Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BioAge, IPO
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement.
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Obesity drug developer
BioAge
Labs (BIOA) has filed regulatory filings as part of its U.S.
IPO
. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at the midpoint. Sofinnova Venture Partners, a leading
BioAge
...
Drugmaker seeks $157.5M in IPO, placement
BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18.
Obesity drugmaker BioAge targets $158 million in IPO
The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday
BioSpace
17d
Lilly Partner BioAge Files for IPO to Advance Obesity Candidate
BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...
pharmaphorum
3d
Respiratory biotech Upstream joins Nasdaq IPO surge
queue amid a flurry of
IPO
activity in the sector, with three biotechs listing on the Nasdaq last week – Bicara ...
Institutional Investor
11d
Hedge Funds Stand to Gain as Biopharma IPOs Heat Up
Meanwhile, late last week, Bicara Therapeutics set terms for its upcoming IPO. The company, which focuses on transformative ...
17d
Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch
After a string of lackluster deals, the biotech industry is looking to four debutants expected to price first-time share ...
1d
U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost
Two small IPOs and two SPACs debuted this past week - Global Engine, Kairos Pharma, YHN Acquisition I, and Cayson Acquisition ...
1d
Initial public offerings scheduled to debut next week
NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.
5d
Capital Markets
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
7d
U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market
Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback